Results 1 to 10 of about 315,728 (345)

Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products [PDF]

Frontiers in Immunology
Chimeric antigen receptor-engineered T cell therapies (CAR-T) are becoming powerful immunotherapeutic tools for treating malignancies, especially hematological malignancies.
Hammodah R. Alfar, Hammodah R. Alfar, Cecil Chen, Eric Lachacz, Weifeng Tang, Yuqian Zhang   +5 more
doaj   +2 more sources

Immunogenicity Risk Profile of Nanobodies

Frontiers in Immunology, 2021
Nanobodies (Nbs), the variable domains of camelid heavy chain-only antibodies, are a promising class of therapeutics or in vivo imaging reagents entering the clinic.
Chloé Ackaert, Natalia Smiejkowska, Catarina Xavier, Yann G. J. Sterckx, Yann G. J. Sterckx, Sofie Denies, Benoit Stijlemans, Benoit Stijlemans, Yvon Elkrim, Nick Devoogdt, Vicky Caveliers, Vicky Caveliers, Tony Lahoutte, Tony Lahoutte, Serge Muyldermans, Karine Breckpot, Marleen Keyaerts, Marleen Keyaerts   +17 more
doaj   +2 more sources

Sleep and vaccine administration time as factors influencing vaccine immunogenicity [PDF]

Kosin Medical Journal, 2022
The immunogenicity of vaccines is affected by host, external, environmental, and vaccine factors; in addition, sleep or circadian rhythms may also have effects.
Eun Seok Kim, Chi Eun Oh
doaj   +1 more source

Immunogenicity of decellularized extracellular matrix scaffolds: a bottleneck in tissue engineering and regenerative medicine

Biomaterials Research, 2023
Tissue-engineered decellularized extracellular matrix (ECM) scaffolds hold great potential to address the donor shortage as well as immunologic rejection attributed to cells in conventional tissue/organ transplantation.
Mohammadreza Kasravi, Armin Ahmadi, Amirhesam Babajani, Radman Mazloomnejad, Mohammad Reza Hatamnejad, Siavash Shariatzadeh, S. Bahrami, H. Niknejad   +7 more
semanticscholar   +1 more source

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

New England Journal of Medicine, 2021
Background Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age.
R. Frenck, N. Klein, N. Kitchin, A. Gurtman, J. Absalon, S. Lockhart, John L. Perez, E. Walter, S. Senders, R. Bailey, K. Swanson, Hua Ma, Xia Xu, K. Koury, W. Kalina, David Cooper, T. Jennings, Donald M Brandon, Stephen J. Thomas, Ö. Türeci, D. Tresnan, Susan H. Mather, P. Dormitzer, U. Şahin, K. Jansen, W. Gruber   +25 more
semanticscholar   +1 more source

A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations

Frontiers in Medicine, 2022
Cell and Gene Therapy Products (CGT), regulated as Advanced Therapy Medicinal Products (ATMP) in the European Union (EU), represent a novel and varied group of biotherapeutics developed to treat specific conditions for which there are limited or no ...
Laura I. Salazar-Fontana, Laura I. Salazar-Fontana, Laura I. Salazar-Fontana   +2 more
doaj   +1 more source

Immunogenicity of lipid nanoparticles and its impact on the efficacy of mRNA vaccines and therapeutics

Experimental and Molecular Medicine, 2023
Several studies have utilized a lipid nanoparticle delivery system to enhance the effectiveness of mRNA therapeutics and vaccines. However, these nanoparticles are recognized as foreign materials by the body and stimulate innate immunity, which in turn ...
Yeji Lee, Michaela Jeong, Jeongeun Park, Hyein Jung, Hyukjin Lee   +4 more
semanticscholar   +1 more source

Human leukocyte antigen class II quantification by targeted mass spectrometry in dendritic-like cell lines and monocyte-derived dendritic cells

Scientific Reports, 2021
The major histocompatibility complex II (HLA-II) facilitates the presentation of antigen-derived peptides to CD4+ T-cells. Antigen presentation is not only affected by peptide processing and intracellular trafficking, but also by mechanisms that govern ...
A. Casasola-LaMacchia, M. S. Ritorto, R. J. Seward, N. Ahyi-Amendah, A. Ciarla, T. P. Hickling, H. Neubert   +6 more
doaj   +1 more source

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study

Annals of the Rheumatic Diseases, 2021
Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic. Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD) are limited.
V. Furer, T. Eviatar, D. Zisman, H. Peleg, D. Paran, D. Levartovsky, M. Zisapel, O. Elalouf, I. Kaufman, R. Meidan, A. Broyde, A. Polachek, J. Wollman, I. Litinsky, K. Meridor, H. Nochomovitz, Adi Silberman, D. Rosenberg, J. Feld, A. Haddad, Tal Gazzit, M. Elias, N. Higazi, F. Kharouf, G. Shefer, O. Sharon, S. Pel, S. Nevo, O. Elkayam   +28 more
semanticscholar   +1 more source

Immunogenicity of autoantigens [PDF]

BMC Genomics, 2011
Autoantibodies against self-antigens have been associated not only with autoimmune diseases, but also with cancer and are even found in healthy individuals. The mechanism causing the autoantibody response remains elusive for the majority of the immunogenic antigens. To deepen the understanding of autoantibody responses, we ask whether natural-occurring,
Eckart Meese, Jana Hoffmann, Petra Leidinger, Hans-Peter Lenhof, Nicole Ludwig, Christian Harz, Christina Backes, Andreas Keller   +7 more
openaire   +4 more sources